ADCs

R&D

Clinical trends for 2025: A year of change

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials.

Patients

pharmaphorum podcast episode 150a - male commuter on train listening to headhones

Can self-navigating ADCs replace chemotherapy in the future?

ADCs are designed to deliver chemotherapy directly to tumours. However, more than 95% of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity.

R&D

Emergence of ADCs as the “hot, new technology”

The recent acquisition of ImmunoGen by AbbVie, which followed the earlier acquisition of Seagen by Pfizer, has brought renewed attention to antibody-drug conjugates (ADCs), highlighting the

News

Pfizer’s new cancer unit sees eight new blockbusters by 2030

Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of invest

R&D

This week in clinical trials: 22nd to 26th January 2024

And so, our weekly clinical trials round-ups continue.

News

Update: Orion buys stake in LegoChem as biotech push goes on

Food group Orion Group has taken a 25% in South Korean biotech LegoChem Bioscience, becoming its largest shareholder, as part of a push into the biotech sector.